Evidence map›Paper›PMID 36428728›Full record

ArticleCancers2022

Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy-A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study.

Nikolaos Spathas, Anna C Goussia, Georgia-Angeliki Koliou, Helen Gogas, Flora Zagouri, Anna Batistatou, Antonia V Charchanti, Alexandra Papoudou-Bai, Mattheos Bobos, Sofia Chrisafi and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Peripheral Blood CD8International journal of molecular sciences · 2024
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Nikolaos SpathasFourth Oncology Department, Metropolitan Hospital, 18547 Athens, Greece.
Anna C GoussiaDepartment of Pathology, Ioannina University Hospital, 45500 Ioannina, Greece.
Georgia-Angeliki KoliouSection of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, 11526 Athens, Greece.
Helen GogasFirst Department of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, 11527 Athens, Greece.ORCID 0000-0002-0451-2885
Flora ZagouriDepartment of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, 11528 Athens, Greece.
Anna BatistatouDepartment of Pathology, Ioannina University Hospital, 45500 Ioannina, Greece.
Antonia V CharchantiDepartment of Pathology, Ioannina University Hospital, 45500 Ioannina, Greece.ORCID 0000-0001-7402-4919
Alexandra Papoudou-BaiDepartment of Pathology, Ioannina University Hospital, 45500 Ioannina, Greece.ORCID 0000-0002-3932-6652
Mattheos BobosLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, 54006 Thessaloniki, Greece.
Sofia ChrisafiLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, 54006 Thessaloniki, Greece.
Kyriakos ChatzopoulosLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, 54006 Thessaloniki, Greece.
Ioannis KostopoulosDepartment of Pathology, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Triantafyllia KoletsaDepartment of Pathology, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0002-4435-3532
Petroula ArapantoniDepartment of Pathology, Henry Dunant Hospital, 11526 Athens, Greece.
Dimitrios PectasidesOncology Section, Second Department of Internal Medicine, Hippokration Hospital, 11527 Athens, Greece.
Eleni GalaniSecond Department of Medical Oncology, Metropolitan Hospital, 18547 Piraeus, Greece.
Angelos KoutrasDivision of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, 26504 Patras, Greece.
George ZarkavelisDepartment of Medical Oncology, Medical School, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0001-5961-2237
Emmanouil SaloustrosDepartment of Oncology, University Hospital of Larissa, 41334 Larissa, Greece.ORCID 0000-0002-0485-0120
Dimitrios BafaloukosFirst Department of Medical Oncology, Metropolitan Hospital, 18547 Piraeus, Greece.
Charisios KaranikiotisDepartment of Medical Oncology, 424 Army General Hospital, 56429 Thessaloniki, Greece.
Iliada BompolakiOncology Department, General Hospital of Chania, 73300 Crete, Greece.
Gerasimos AravantinosSecond Department of Medical Oncology, Agii Anargiri Cancer Hospital, 14564 Athens, Greece.
Amanda PsyrriSection of Medical Oncology, Department of Internal Medicine, Attikon University Hospital, Faculty of Medicine, National and Kapodistrian University of Athens School of Medicine, 12462 Athens, Greece.
Evangelia RazisThird Department of Medical Oncology, Hygeia Hospital, 15123 Athens, Greece.
Anna KoumarianouHematology-Oncology Unit, Fourth Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens School of Medicine, 12462 Athens, Greece.ORCID 0000-0002-4159-2511
Eleni ResThird Department of Medical Oncology, Agii Anargiri Cancer Hospital, 14564 Athens, Greece.
Helena LinardouFourth Oncology Department, Metropolitan Hospital, 18547 Athens, Greece.ORCID 0000-0002-2906-6607
George FountzilasLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, 54006 Thessaloniki, Greece.ORCID 0000-0001-8045-2186

Funding

Hellenic Cooperative Oncology Group N/AHellenic Society for Medical Oncology N/A
6 · The paper itself

Abstract

Tumor-infiltrating lymphocytes (TILs) contribute to breast cancer (BC) prognosis. We investigated the prognostic impact of CD8+ TILs in patients with early breast cancer treated with adjuvant chemotherapy in a large observational clinical trial. Along with a 10 year follow-up, considering the efficacy and safety, we report the results of the translational part of our study. We examined the patients' tumors for total (t), stromal (s), and intratumoral (i) CD8 lymphocyte density (counts/mm

Indexed as

adjuvant chemotherapybiomarkersbreast cancertumor-infiltrating lymphocytes

Identifiers

PMID36428728
PMCPMC9688913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.